Literature DB >> 18326526

Hepatocyte growth factor promotes migration of human myeloma cells.

Randi Utne Holt1, Unn-Merete Fagerli, Vadim Baykov, Torstein Baade Rø, Håkon Hov, Anders Waage, Anders Sundan, Magne Børset.   

Abstract

Multiple myeloma is characterized by the accumulation and dissemination of malignant plasma cells in the bone marrow. Cell migration is thought to be important for these events. We studied migration in a Transwell two-chamber assay and tested the motogenic effect of various cytokines. In addition to insulin-like growth factor-1 and stromal cell-derived growth factor-1alpha, previously known as chemoattractants for myeloma cells, we identified hepatocyte growth factor as a potent attractant for myeloma cells. Hepatocyte growth factor-mediated migration was dependent on phosphatidylinositol-3-kinase, involved the MAPK/Erk signaling cascade and VLA-4 integrins, but did not involve Akt, mTOR or G proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326526     DOI: 10.3324/haematol.11867

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  13 in total

1.  Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.

Authors:  Anurag Purushothaman; Bryan P Toole
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

2.  Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis.

Authors:  Toru Takahashi; Tomofumi Miura; Junichiro Nakamura; Satoshi Yamada; Tsutomu Miura; Masahiko Yanagi; Yasunobu Matsuda; Hiroyuki Usuda; Iwao Emura; Koichi Tsuneyama; Xiao-Song He; M Eric Gershwin
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

3.  The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells.

Authors:  Ida Steiro; Esten N Vandsemb; Samah Elsaadi; Kristine Misund; Anne-Marit Sponaas; Magne Børset; Pegah Abdollahi; Tobias S Slørdahl
Journal:  Oncotarget       Date:  2022-10-20

4.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

5.  Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Authors:  Erming Tian; Magne Børset; Jeffrey R Sawyer; Gaute Brede; Thea K Våtsveen; Håkon Hov; Anders Waage; Bart Barlogie; John D Shaughnessy; Joshua Epstein; Anders Sundan
Journal:  Genes Chromosomes Cancer       Date:  2015-07-29       Impact factor: 5.006

6.  Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma.

Authors:  C A Pappa; G Tsirakis; F E Psarakis; A Kolovou; M Tsigaridaki; D Stafylaki; K Sfiridaki; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-12-25       Impact factor: 3.064

7.  Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Jiri Minarik; Tomas Pika; Jaroslav Bacovsky; Pavla Petrova; Katerina Langova; Vlastimil Scudla
Journal:  ScientificWorldJournal       Date:  2012-04-26

8.  c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Authors:  Håkon Hov; Erming Tian; Toril Holien; Randi Utne Holt; Thea K Våtsveen; Unn-Merete Fagerli; Anders Waage; Magne Børset; Anders Sundan
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997

9.  Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.

Authors:  Cuiping Yang; Jing Wang; Dengyu Chen; Junsong Chen; Fei Xiong; Hongyi Zhang; Yunxia Zhang; Ning Gu; Jun Dou
Journal:  Int J Nanomedicine       Date:  2013-04-12

10.  Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.

Authors:  K F Wader; U M Fagerli; R U Holt; B Stordal; M Børset; A Sundan; A Waage
Journal:  Eur J Haematol       Date:  2008-08-06       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.